跳到正文
原文
FierceBiotech· @FierceBiotech · X·· 1 小时前精选AI 评分72
AI 导读

渤健的tau靶向阿尔茨海默病疗法在96周时与临床衰退减缓38%相关,为后期开发增添依据。该结果出现在一项数据不一的II期研究之后。

推荐理由

原文给出96周时38%的临床衰退减缓幅度,读者可据此判断该tau靶向疗法在II期数据不一后的后续开发空间。

正文

Biogen's tau-targeting Alzheimer's therapy was linked to a 38% slowing of clinical decline at 96 weeks, strengthening the case for late-stage development despite a mixed phase 2 readout. https://www.fiercebiotech.com/biotech/biogens-tau-therapy-drives-bigger-benefits-2-year-alzheimers-update

来源:FierceBiotech · x.com